The impact of hidradenitis suppurativa on professional life.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
23 01 2023
23 01 2023
Historique:
received:
19
08
2022
revised:
19
09
2022
accepted:
24
09
2022
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
ppublish
Résumé
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects intertriginous skin. To determine the extent of work ability and productivity impairment as a result of HS in Germany. A prospective, multicentre, epidemiological, noninterventional study of patients with HS was conducted. Medical history, medical examination performed by dermatologists and patient-reported outcomes [Work Ability Index (WAI) and Work Productivity and Activity Impairment (WPAI)] were collected. Of the 481 patients with HS included in the study, 99% were below the current statutory retirement age. In total, 53·3% of patients were working full time, 16·8% part time and 7·3% had retired. The unemployment rate was 12·6%, two times higher than in the general German population. Medical leave because of HS, within the last 6 months, was reported in 41·4% [95% confidence interval (CI) 36·9-46·0], with a duration of 39·3 days on average (95% CI 32·4-46·1). The mean HS-related WPAI absenteeism was 13.3% (95% CI 9·7-16·8), and the loss in productivity because of HS during working hours (WPAI presenteeism) was 25.2% (95% CI 21·8-28·6). Presenteeism was associated with HS disease severity. Overall work impairment because of HS was 33·4% (95% CI 29·3-37·6). The WAI score for patients was 32·2, ∼20% lower than for the average German employee. Only 62·8% of patients were relatively certain that they would be able to perform their work in the coming 2 years. Being more depressed and having more severe pain were associated with lower work ability and overall work impairment. The estimated annual loss of gross value added because of HS for Germany was ∼€12.6 billion (€3.3 billion related to a lower employment rate, €3.5 billion related to absenteeism and €5.8 billion related to presenteeism). HS leads to a substantial decrease in work ability and productivity and considerable loss of gross value added. Impairment during working hours correlates with disease severity, underlining the socioeconomic importance of early and adequate treatment. Furthermore, decreased work ability and productivity is linked to depressed mood and severe pain, aspects that need more attention in patient care.
Sections du résumé
BACKGROUND
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that affects intertriginous skin.
OBJECTIVES
To determine the extent of work ability and productivity impairment as a result of HS in Germany.
METHODS
A prospective, multicentre, epidemiological, noninterventional study of patients with HS was conducted. Medical history, medical examination performed by dermatologists and patient-reported outcomes [Work Ability Index (WAI) and Work Productivity and Activity Impairment (WPAI)] were collected.
RESULTS
Of the 481 patients with HS included in the study, 99% were below the current statutory retirement age. In total, 53·3% of patients were working full time, 16·8% part time and 7·3% had retired. The unemployment rate was 12·6%, two times higher than in the general German population. Medical leave because of HS, within the last 6 months, was reported in 41·4% [95% confidence interval (CI) 36·9-46·0], with a duration of 39·3 days on average (95% CI 32·4-46·1). The mean HS-related WPAI absenteeism was 13.3% (95% CI 9·7-16·8), and the loss in productivity because of HS during working hours (WPAI presenteeism) was 25.2% (95% CI 21·8-28·6). Presenteeism was associated with HS disease severity. Overall work impairment because of HS was 33·4% (95% CI 29·3-37·6). The WAI score for patients was 32·2, ∼20% lower than for the average German employee. Only 62·8% of patients were relatively certain that they would be able to perform their work in the coming 2 years. Being more depressed and having more severe pain were associated with lower work ability and overall work impairment. The estimated annual loss of gross value added because of HS for Germany was ∼€12.6 billion (€3.3 billion related to a lower employment rate, €3.5 billion related to absenteeism and €5.8 billion related to presenteeism).
CONCLUSIONS
HS leads to a substantial decrease in work ability and productivity and considerable loss of gross value added. Impairment during working hours correlates with disease severity, underlining the socioeconomic importance of early and adequate treatment. Furthermore, decreased work ability and productivity is linked to depressed mood and severe pain, aspects that need more attention in patient care.
Identifiants
pubmed: 36689513
pii: 6770097
doi: 10.1093/bjd/ljac027
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
122-130Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Association of Dermatologists.
Déclaration de conflit d'intérêts
Conflicts of interest: S.S.-B. has received honoraria for participation in advisory boards, in clinical trials and/or as speaker from AbbVie Inc, AbbVie Deutschland GmbH & Co. KG, Novartis Pharma GmbH, UCB Pharma, Biogen GmbH, Moonlake and Pfizer Deutschland GmbH. S.K. is an employee of GKM (Gesellschaft für Therapieforschung mbH, a clinical research organization) contracted for data analysis, which was funded by AbbVie. B.F. and S.G.-K. are employees of AbbVie Deutschland GmbH & Co KG and may own AbbVie stocks or options. K.W. has received research grants, travel grants, consulting honoraria or lecturer’s honoraria from AbbVie Inc, AbbVie Deutschland GmbH & Co, Celgene/BMS, Charité Research Organisation GmbH, Dr Willmar Schwabe GmbH & Co KG, Flexopharm GmbH & Co KG, JanssenCilag GmbH, Novartis Pharma GmbH, Pfizer Deutschland GmbH, Sanofi–Aventis Deutschland GmbH, TFS GmbH and UCB Biopharma SPRL. R.S. has received research grants or honoraria for participation in advisory boards, clinical trials, or as speaker for one or more of the following: AbbVie Inc, AbbVie Deutschland GmbH & Co KG, Amgen GmbH, Bayer Schering Pharma AG, Boehringer Ingelheim Pharma GmbH & Co KG, Celgene GmbH, Celgene International II Sàrl, Charité Research Organisation GmbH, CSL Behring, Dr Willmar Schwabe GmbH & Co KG, Flexopharm GmbH & Co KG, ICON plc, Incyte Corporation, JanssenCilag GmbH, La Roche-Posay Laboratoire Dermatologique, MoonLake Immunotherapeutics AG, Novartis Pharma GmbH, Parexel International GmbH, Sanofi–Aventis Deutschland GmbH, TFS GmbH and UCB Biopharma SPRL.